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Eloisa Jantus-Lewintre8,9, Rafael López10, Laura Muinelo-Romay10, Clara Montagut11, Antonio Antón12, Guillermo López13,
Eduardo Díaz-Rubio14, Federico Rojo15 and Ana Vivancos16
BACKGROUND: Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The
goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal
cancer (CRC) patients at 10 hospital laboratories in Spain where this technology is routinely implemented.
METHODS: Circulating cell-free DNA from plasma was examined for RAS mutations using the OncoBEAM platform at each hospital
laboratory. Results were then compared to those obtained from DNA extracted from tumour tissue from the same patient.
RESULTS: The overall percentage agreement between plasma-based and tissue-based RAS mutation testing of the 236 participants
was 89% (210/236; kappa, 0.770 (95% CI: 0.689–0.852)). Re-analysis of tissue from all discordant cases by BEAMing revealed two
false negative and five false positive tumour tissue RAS results, with a final concordance of 92%. Plasma false negative results were
found more frequently in patients with exclusive lung metastatic disease.
CONCLUSIONS: In this first prospective real-world RAS mutation performance comparison study, a high overall agreement was
observed between results obtained from plasma and tissue samples. Overall, these findings indicate that the plasma-based
BEAMing assay is a viable solution for rapid delivery of RAS mutation status to determine mCRC patient eligibility for anti-EGFR
therapy.
British Journal of Cancer (2018) 119:1464–1470; https://doi.org/10.1038/s41416-018-0293-5
INTRODUCTION
Colorectal cancer (CRC) remains one of the most common cancers
worldwide, and accounts for 12% of all cancer-related deaths in
Europe.1 The epidermal growth factor receptor (EGFR) has become
an important therapeutic target in CRC,2 but ~40% of patients
with metastatic colorectal cancer (mCRC) have tumours with
mutations in KRAS and are not expected to respond to treatment
with the anti-EGFR monoclonal antibodies cetuximab and
panitumumab.3,4 Several studies have shown that an extended
analysis of RAS mutations (including KRAS exons 2, 3, and 4 and
NRAS exons 2, 3, and 4) may optimise the identification of patients
most likely to benefit from anti-EGFR therapy,5–9 and clinical
practice guidelines in the US and Europe include the indication for
expanded RAS testing before the use of anti-EGFR agents.10–12
Typically, the evaluation of RAS mutation status requires
the acquisition of tumour tissue, subsequent processing to
formalin-fixed, paraffin-embedded (FFPE) specimens and molecu-
lar testing with various techniques. As an alternative, the analysis
of circulating tumour DNA (ctDNA) can provide a rapid genotype
result with a streamlined clinical workflow and minimal dis-
turbance to the patient. The recent approval of the OncoBEAM
RAS CRC liquid biopsy assay by the European Commission as an
in vitro diagnostic tool allows a practical and sensible approach
for determination of RAS mutations in ctDNA.13
In this study, which included 10 hospital centres across Spain
certified to run OncoBEAM RAS in routine practice, we evaluated
the concordance between RAS status determined by OncoBEAM in
plasma and the reference test performed on tissue at each centre
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from a large cohort of mCRC patients. We also examined the
characteristics of discordant cases and the mutant allele fraction
(MAF) in RAS mutated patients.
PATIENTS AND METHODS
Study design and patients
This was a multicenter, prospective, real-world study performed in
10 Spanish centres from November 2015 to October 2016. The
study was approved by the Institutional Review Board at each
hospital and was conducted in accordance with the principles of
the Declaration of Helsinki. Prior to participation, all patients
signed the inform consent form. Newly-diagnosed mCRC patients
or presenting with recurrent disease after resection and/or
chemotherapy were eligible. Patients having surgery with total
disease removal or that received the last cycle of chemotherapy
<6 months prior to blood draw were excluded.
Procedures
Plasma was obtained from 10ml of blood collected in Streck cell-
free DNA BCT® or EDTA tubes before any therapeutic intervention.
All patients had FFPE tissue (either primary tumour or metastasis)
available for mutation analysis. OncoBEAM™ RAS CRC assay,
which detects 34 mutations in KRAS/NRAS codons 12, 13, 59, 61,
117, and 146, was used to analyse RAS mutations and determine
MAF in plasma. The mutation profile in tissue samples was
determined by standard-of-care (SoC) procedures validated by
each hospital (Supplementary Table S1). Tissue RAS testing by
BEAMing (1% mutant allele cut-off) was centrally performed
by the Service Laboratory of Sysmex Inostics. The commercially
available mutation testing service using the RAS OncoBEAM panel
(33 single mutations, covering the same base exchanges like the
IVD kit product OncoBEAM™ RAS CRC assay) was used in the
laboratory of Sysmex Inostics GmbH, Hamburg (Germany) on FFPE
samples from every patient case where the SoC RAS result was
discordant with the plasma RAS result. The same tissue block was
used for the central re-analysis by BEAMing.
Statistical analysis
Categorical variables were summarised in numbers and percen-
tages, continuous variables were presented as medians, minima
and maxima. Concordance between plasma and tissue RAS
testing was determined using a Kappa statistic (kappa) with 95%
confidence interval (CI). Positive percent agreement (PPA),
negative percent agreement (NPA) and overall percent agreement
(OPA) were also calculated. For MAF levels correlations with
clinical variables, we performed non-parametric statistics
(Mann–Whitney U test for dichotomous and Kruskal–Wallis test
for polychotomous variables). All statistical tests were considered
significant when P < 0.05. Statistical analyses were performed
using the SAS version 9.4 statistical software.
RESULTS
Patient characteristics and RAS mutation status analysis from
plasma and tissue
A total of 239 mCRC patients were initially included, 3 of which
were excluded because total disease removal during primary
surgery. The remaining 236 participants, 144 men and 92 women,
comprised the study population (see their baseline characteristics
in Table 1). The majority of patients (95.4%) had colorectal
adenocarcinoma with distant metastases at diagnosis (85.1%),
50.4% underwent surgery to remove the primary tumour or some
portion of metastasis (16.9%) before blood sample collection.
The most frequent site of metastasis was the liver (71.2%) followed
by the lung (29.3%).
RAS mutation status was evaluable in both plasma and tissue
of all 236 patients. Overall, RAS mutations were detected in
55.5% of tumour-tissue samples and in 51.3% of plasma samples
(Table 1). The OPA of RAS results between ctDNA and SoC for
tissue analysis was 89% (210/236 patients), with a kappa
index of 0.770 (95% CI: 0.689–0.852) (Fig. 1a). To clarify the 26
discrepant RAS status results, all FFPE samples except one (not
available) were centrally re-analysed by BEAMing technology
(Table 2). Of the 18 plasma WT/RAS+ cases, five were finally
concordant (Plasma WT/Tissue SoC Mutated/Tissue BEAMing
WT); of the 8 plasma RAS+/tissue WT cases, two were
concordant (Plasma BEAMing Mutated/Tissue SoC WT/Tissue
BEAMing Mutated). This final analysis resulted in a total 217
concordant patients from the 236, representing a 92% overall
concordance (κ: 0.853, 95% CI: 0.786–0.920) (Fig. 1b).
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Liver (only in liver) 168 (90) 71.2% (38.1%)
Lung (only in lung) 69 (16) 29.3% (6.8%)
Peritoneal (only peritoneal) 63 (25) 26.7% (10.6%)
Other (only other) 46 (14) 19.5% (5.9%)













Median (range) 2.9 (0–68) —
MAF Mutated allele fraction, SOC standard of care, WT wild-type
Prospective multicenter real-world RAS mutation comparison between. . .














Discordant samples description and factors affecting concordance
Among the samples with discordant RAS status between ctDNA
and tissue BEAMing (n= 19), we observed that 5 of 13 Plasma
WT/RAS+ Tissue cases involved patients that had exclusively lung
metastases (Table 2). Among the group with RAS+ Plasma/Tissue
WT discordance, the sites of metastases in these 6 patients were
widely distributed, including locations such as ovary and bone.
Table 3 shows concordant/discordant paired samples according
to different clinical and pathological factors. Concordance was
lower (87.4% vs 95.7%; P= 0.033) in cases where primary tumour
surgery was initially performed. Those with metastatic disease at
diagnosis had a higher agreement than patients without
metastasis (94.5% vs 78.1%; P= 0.006). A higher concordance of
plasma and tissue RAS results was observed in patients having liver
metastases (94.5–94.8%) versus those not having liver metastases
(83.8%; P= 0.040), whereas the lowest concordance rate was
associated with the presence of lung metastases only (68.8%).
MAF analysis in mutated plasma samples
For the 121 patients with detectable plasma RAS mutations, the
median MAF [range] was 2.9% [0–68]. No differences in mutational
load were observed in relation to age, tumour histology,
metastasis at diagnosis, or primary site of disease (Table 3). The
median MAF in ctDNA according to the number of metastatic sites
was 2% [0–68] in those with one metastatic site, 3.9% [0–35.7] in
those with two metastatic sites, and 13% [0.3–51.8] in those with
three or more (P= 0.074). The median MAF for those with at least
one liver metastasis was 6.7% [0–51.8], whereas the patients with
metastases only in the lung showed a median of 0.7% [0.1–24.7].
DISCUSSION
A timely assessment of the current RAS mutation profile of mCRC
patients provides the opportunity to deliver the most optimal
therapy regimen matched to tumour molecular status.14 With a
liquid biopsy we can determine the presence of circulating
tumour cells (CTCs), cancer‐derived exosomes, and ctDNA. Despite
the technological advances in identifying and characterising CTCs,
there are still significant biological challenges that limit their
clinical application.15 As ctDNA is released from primary tumours,
CTCs, micrometastasis or overt metastases, this might better
reflect the molecular changes that occur during disease progres-
sion.16 Mutations in ctDNA may be detected in blood using several
techniques, such as digital PCR (dPCR) assays such as droplet-
digital PCR (ddPCR) and BEAMing, or next-generation sequencing
(NGS). dPCR platforms offer easy workflow and better allele-
specific sensitivity and reproducibility than standard quantitative
PCR, but are limited in its multiplexing capability.17 When multiple
targets have to be analysed, NGS technology reduces the cost of
screening compared to analysis with a lower throughput
technology.18 The principles and different characteristics of these
techniques have been reviewed elsewhere.13,19
To the best of our knowledge, this is the first prospective real-
world study in which a RAS mutational analysis was compared
between plasma OncoBEAM RAS CRC assay and tissue-based
techniques in a network of hospital laboratories certified to
perform OncoBEAM testing in routine clinical practice. Overall, a
high concordance rate of RAS status was observed between
plasma and tissue analysis performed by SoC procedures (89%).
This rate was even better when certain tissue specimens which
were seemingly mischaracterised by the local SoC technique were
re-evaluated with BEAMing (92%). These results support the use of
plasma testing with the OncoBEAM platform as a valuable
alternative to tissue SoC to identify patients eligible for anti-
EGFR therapy in routine clinical practice. Moreover, concordance
rates are comparable to those obtained in previous retrospective
and prospective studies,20–22 which corroborate the consistency of
the technique among different mCRC patient populations. In fact,
the frequency of RAS mutations in patients evaluated in this study
was in agreement with the results of other groups performing
expanded RAS analysis (plasma 51.3%; tissue 55.5%).21–23
Some reports have demonstrated that testing of DNA from a
single colorectal tumour tissue block will wrongly assign KRAS
wild-type status in 8–11.6% of patients.24,25 Thus, the sole reliance
on RAS mutation results obtained from a primary tumour sample
might misinform effective treatment of residual systemic disease,
imposing significant costs both clinically and financially. This
sampling bias could largely be avoided by determining the
RAS mutational status on multiple tumour blocks, but this is
neither practical nor feasible. Studies evaluating inter-tumour
heterogeneity between primary tumours and metastases have
also revealed mutational discordance in a significant proportion
of cases26–28 with high levels of inter-tumour heterogeneity
observed between primary tumour and matched lung metastases
(32.4%).27 Thus, mCRC patients eligible for surgical resection can
have primary tumours with a RAS mutation and metastases
without RAS mutations, and vice-versa. Though there is no
definitive guideline for determining which sample should be
tested for RAS mutations, it is often the case in metastatic disease
that the primary site is surgically resected while distant metastases
are treated with systemic therapy.
Previous studies have shown that BEAMing is an accurate
technique for the mutational analysis of archival FFPE tumour
tissue.6,8,29 In the present study, we found seven cases in which
BEAMing identified the same RAS mutation in tissue that was
identified in plasma, contrary to the original SoC result.
Differences in tissue RAS mutation detection capabilities ranging
between 3 and 20% among diverse routine methodologies have
been reported,30–32 possibly associated with different sensitivity
thresholds.20 Accordingly, the agreement between plasma and
tissue RAS testing results will likely improve when both the
methods of plasma and FFPE preparation are standardised,
underlying the importance of selecting a reliable laboratory for
routine testing.33 In our population, 13 patients had mutations in
tissue that could not be detected in plasma, which may be
attributed to tumour heterogeneity, low ctDNA shedding or low
tumour burden. In fact, five of these discordant cases had archival










Mutation detected 113 8 121
18 97 115
Total 131 105 236
Overall percent agreement = 89.0%
Positive percent agreement = 86.3%
Negative percent agreement = 92.4%











Mutation detected 115 6 121
13 102 115
Total 128 108 236
Overall percent agreement = 92.0%
Positive percent agreement = 89.8%
Negative percent agreement = 94.4%
b
Fig. 1 Concordance between plasma and tissue results obtained by
SOC (a) or SOC+ BEAMing (b). SOC standard of care
Prospective multicenter real-world RAS mutation comparison between. . .
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Prospective multicenter real-world RAS mutation comparison between. . .

































































































































































































































































































































































































































































Table 3. Plasma BEAMing vs tissue SOC+ BEAMing concordance
according to clinical and pathological variables





≤65 87.6 0.824 3.3 (0–68) 0.459
>65 88 2.7 (0–51.8)
Primary tumour resection
No 95.7 0.033 6.9 (0–68) 0.049
Yes 87.4 1.8 (0–26.8)
Metastasis resection
No 93.4 0.007 3.9 (0–68) 0.169
Yes 79.1 1.3 (0–24.6)
Histological type
Adenocarcinoma
92 0.236 3.5 (0–68) 0.080
Other 81.8 0.2 (0–15.1)
Metastases at diagnosis
No 78.1 0.006 3.9 (0.2–24.7) 0.319
Yes 94.5 2.6 (0–68)
Primary tumour location
Left 96.2 0.483 3.9 (0–51.8) 0.351
Right 89.9 2.8 (0–68)
Not available 100 11.7 (11.4–12)
Number of metastases
1 91 1.000 2 (0–68) 0.074
2 91.9 3.9 (0–35.7)

































Source of tissue sample




MAF mutated allele fraction, SOC standard of care
Bold values to remark a statistically significant difference
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primary tumour mutated and excised, maybe their metastases
were WT or low-shedding lesions. Other authors found similar
results in patients with RAS mutant on tissue and WT on liquid
biopsy that had recurrence of the disease after surgical resection
of the primary and a lower tumour burden, with metastatic lesions
often localised in the lung and lymph nodes.34 This finding is
consistent with the significantly lower MAF found in our cohort of
patients subjected to primary tumour resection. In line with this,
our results also showed that the degree of RAS mutational
concordance varied according to the metastatic site, with more
discrepancies in patients with lung only metastases and a higher
agreement in liver metastases; similarly, Thierry et al found higher
specificity of plasma mutation analysis in patients with at least
one liver metastasis,35 whereas Kim et al.,27 reported higher
discordance rates when compared paired primary tumour and
lung samples, so it is possible that lung metastases more
frequently have a different RAS status than other metastatic sites.
Another explanation may be that tumour budding in the
metastatic lesions triggers different levels of ctDNA release.
Metastatic deposits in the liver are likely highly vascularised as
compared to the lungs, and this may contribute to greater levels
of ctDNA released in the bloodstream.
Here, the median MAF obtained by plasma BEAMing was 2.9%,
higher than in Vidal et al. (1.84%)22 but lower than Schmiegel et al.
(6.82%).21 In the first study, 8 of the 59 RAS+ patients had received
previous treatment with chemotherapy ± anti-VEGF within a
month prior ctDNA blood extraction and showed significantly
lower RAS plasma MAF as compared to treatment-naive patients,
whereas our population had at least 6 treatment-free months
before plasma collection. It has been reported that changes in
ctDNA may occur during the course of the chemotherapy, with
significant reductions in ctDNA levels observed even after the first
cycle.29 Thus, mutational load in patients exposed to therapy may
decrease in parallel to radiological response.36,37 Indeed, Schmie-
gel et al.21 included a cohort of stage IV newly diagnosed patients
with intact primary CRC whose MAF was 6.5-fold higher (9.63%)
compared with those patients who presented with recurrent
disease after removal of their primary tumours (1.49%). These
findings highlight the significance of determining and monitoring
the MAF of RAS+ mCRC patients throughout the course of the
disease management and the impact of any surgical procedure
and/or systemic treatment on it. Moreover, based on our results,
the rate of release of tumour DNA into circulation may serve as an
important clinical observation to consider, as highly vascularised
metastatic sites (i.e. liver) and an elevated number of metastases
were associated with higher MAF values.
In conclusion, ctDNA analysis by OncoBEAM RAS CRC assay is
comparable to SoC tissue testing techniques. It represents a
minimally invasive method easily implemented in routine clinical
practice to rapidly determine mCRC patient eligibility for anti-EGFR
therapy. This technique likely avoids the potential pitfalls of
selecting a targeted therapy strategy based on the molecular
profile of a single lesion. A unique feature of ctDNA genotyping is
its ability to evaluate the extent of an individual patient’s tumour
burden, eliminating sampling issues related to tissue molecular
heterogeneity and the development of mutations during the
metastatic process.
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